Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Sheila Gujrathi is Chief Strategy Officer at Bolt Biotherapeutics. OQRO lists 6 transactions filed with the SEC under this name, the latest on Oct 27, 2026, each linked to the official Form 4.
Chief Strategy Officer
Disclosures on record
6
Companies involved
2
Sheila Gujrathi bought shares on the open market in 2019, and has not bought since 2019.
Sheila Gujrathi reported 1 open-market purchase and 0 sales since 2019; purchases in 2019.
| Year | Bought | Sold |
|---|---|---|
| 2019 | $168K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Bolt BiotherapeuticsBOLT
4 disclosures · Oct 2026
Oct 23, 202673Kdisclosed Oct 27
DetailsOfficial recordOct 23, 202613Kdisclosed Oct 27
DetailsOfficial recordOct 23, 20262,763.83disclosed Oct 27
DetailsOfficial recordOct 23, 2026495.87disclosed Oct 27
DetailsOfficial recordProcessa PharmaceuticalsPCSA
2 disclosures · Jul 2026
Jul 28, 202671Kdisclosed Jul 31
DetailsOfficial recordJul 28, 202612Kdisclosed Jul 31
DetailsOfficial recordAs of the latest filing on , Sheila Gujrathi reported holding 85,821 shares of Bolt Biotherapeutics (BOLT), worth about $522K at the last close of $6 (Nov 13, 2026): 72,766 held directly and 13,055 through a silverarc private fund i, l.p.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Bolt Biotherapeutics BOLT | 85,821 | 73K direct · 13K silverarc private fund i, l.p | $6 | $522K | Oct 23, 2026 |
Is this Sheila Gujrathi’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Oct 23, 2026, Sheila Gujrathi reported holding 85,821 shares of Bolt Biotherapeutics (BOLT), of which 13,055 are held indirectly. At the last close of $6 on Nov 13, 2026, that is about $522K. This is the stake disclosed in filings, not a net worth.
Sheila Gujrathi bought shares on the open market in 2019, and has not bought since 2019.
In SEC filings since 2019: the latest open-market purchase is from 2019; no open-market sale is on record.
Gossamer Bio (GOSS), from 2019 to 2019: 1 purchase and 0 sales.
Sheila Gujrathi reported 1 open-market purchase and 0 sales here, 2019.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
